Compliance Corner: Podcasts

In this episode, Suzanne Spradley and Chase Cannon break down the Senate’s version of the One Big Beautiful Bill, released on June 16, 2025. Suzanne outlines the budget reconciliation process and how the so-called “Byrd Rule” comes into play. Suzanne and Chase discuss the similarities and differences between the House and Senate versions of this bill and how the two can align on those differences. Suzanne outlines one major difference relating to the Senate’s exclusion of certain benefit-related provisions (HRA/CHOICE/ICHRA amendments and HSA expansions and flexibilities, to name a few) that were in the House’s version. Suzanne and Chase conclude with thoughts on what employers can expect in the coming weeks as the legislative process plays out.

In this episode, Chase Cannon and Suzanne Spradley outline the latest proposed bill from the U.S. House of Representatives, potentially up for a vote in the coming weeks. Chase outlines a key element missing from the proposed bill ‒ caps, cuts, or elimination of the so-called employer tax exclusions for health insurance ‒ and explains why it’s important for employer health plan sponsors. Chase and Suzanne spend the rest of the episode describing potential changes to HSAs and HRAs, including flexibility with HSA eligibility, increases on HSA contribution limits, and a new vehicle (called a “CHOICE arrangement”) for reimbursing an employee’s individual policy premium.

In this episode, Suzanne Spradley and Chase Cannon review a recent industry focus-study on the economic impact of capping or eliminating the tax benefits associated with employer-provided health plans. Suzanne begins by providing a background on the employer-sponsored insurance tax breaks, their impact on employers and employees, and why Congress is considering a potential cap or elimination of those tax breaks. Suzanne and Chase discuss a recent study that addresses the negative downstream impact of such a cap or elimination, including detrimental economic, health insurance coverage, and health outcomes. Employers should be aware of these impacts and outcomes as Congress continues to view healthcare tax benefits as a source of revenue to offset other tax credits and breaks, including those that Congress wants to extend as part of the Tax Cuts and Jobs Act (which is set to expire at the end of 2025).

In this episode, Chase Cannon and Suzanne Spradley discuss some interesting questions relating to health savings accounts (HSAs), including basic eligibility, impermissible coverage, and employer responsibility when determining an individual employee’s HSA eligibility. Chase jumps in on a response to a question about HSA eligibility regarding a health FSA grace period. Chase and Suzanne conclude with a discussion about Medicare enrollment and HSA eligibility and whether employers should automatically terminate HSA contributions when an employee turns 65.

In this episode, Suzanne Spradley and Chase Cannon discuss recently published proposed regulations relating to HIPAA’s Security Rule. Suzanne leads off with an overview of the HIPAA privacy and security rules generally, focusing on security — the usage of personal health information in electronic form. Suzanne and Chase discuss potential changes in definitions under HIPAA’s Security Rule, how the risk analysis requirement might be impacted, and what employers should be considering with their internal benefits, technology, and IT teams. Suzanne closes the podcast with her thoughts on the process and timeline for finalizing the proposed regulations.

In this episode, Suzanne Spradley and Chase Cannon discuss the debate relating to employer-sponsored group health plan coverage and insurance tax exclusion. Suzanne describes what is meant by employer-sponsored insurance (ESI) and the background on the tax breaks that employers and employees receive when it comes to ESI. Suzanne and Chase walk through the two sides of the debate on keeping or remodeling the ESI tax exclusion, which could become a bigger issue in 2025 with respect to tax and health policy under the constantly changing legislative environment in DC.

In this episode, Chase Cannon and Suzanne Spradley discuss the recent revival of vendor-promoted pre-tax wellness arrangements that promise large tax savings for employers and employees with little employer investment. Chase leads off with a brief description of these programs and their purported claims on employment tax savings for both employees and employers. Chase and Suzanne review the various iterations of the programs, explain how their tax-free reimbursements are not allowed under the related rules, and discuss how the IRS has attempted to address their illegitimacy through several pieces of guidance. Chase closes out the podcast by identifying red flags to help listeners recognize these problematic programs.

In this episode, Suzanne Spradley and Chase Cannon review the current state and federal regulation of pharmacy benefit managers (PBMs), focusing on litigation surrounding recent state-enacted PBM rules. Suzanne starts off with a high-level description of PBMs and the role they play in the group health plan context. Suzanne and Chase discuss the plethora of state laws (proposed and enacted) focused on PBM regulation and the role courts have played in ERISA preemption of state laws, including in Arkansas, Oklahoma, and North Dakota. Suzanne concludes with a discussion of ERISA fiduciary obligations in the context of the J&J lawsuit, including a few employer takeaways on establishing a process for making plan-related decisions on pharmacy and other benefits and administration.

In this episode, Suzanne Spradley and Chase Cannon discuss the US importation policies and rules aimed at lowering domestic prescription drug costs. Suzanne walks through the legalities of drug importation generally and then outlines the specific programs by which states can develop importation plans. Chase and Suzanne discuss several state importation proposals and how they could potentially bring savings to US consumers. Suzanne closes by addressing Canadian concerns relating to potential US drug importation.